Oragenics, Inc. (OGEN) - Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K was filed by Oragenics, Inc. on April 5, 2013. The report addresses a corporate event regarding the listing of the Company's common stock.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on a listing approval and does not contain financial performance data.
Material Changes
- Stock Listing Approval: On April 5, 2013, the Company was notified that its common stock was approved for listing on the NYSE: MKT.
- Trading Commencement: Trading is expected to begin on Wednesday, April 10, 2013, under the ticker symbol OGEN.
Guidance, Outlook, and Risks
The filing contains no management commentary, financial guidance, risk factors, or contingencies beyond the notification of the stock exchange listing. No unusual items were reported.
Investor Verification Checklist
- Confirm the start of trading on the NYSE: MKT on April 10, 2013, under ticker OGEN.
- Review the attached press release (Exhibit 99.1) for additional details on the listing.
- Verify the Company's financial status in subsequent periodic reports (10-K or 10-Q) as this 8-K contains no financial data.